Tirzepatide

FDA-approved

Calculate Dose

For research use only.

Key Facts

CAS: 2023788-19-2
Molecular Weight (MW): ≈4813 g/mol
Half-life: ~5 days
Unit: mcg
Administration Route: Subcutaneous
Frequency: Once weekly
Last updated: 12/14/2025
Targets: GIP receptorGLP-1 receptorPancreatic beta cellsCentral nervous system

Overview

—

Protocol

Dosage Range: 2.5-15 mg weekly (titrated)
Frequency: Once weekly
Cycle: Long-term use as prescribed
Administration Route: Subcutaneous
Reconstitution Guide: Prefilled pen - no reconstitution needed

Science

Mechanism of Action

Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. It activates both receptors, providing enhanced glucose control and weight loss compared to GLP-1-only agonists.

Targets

GIP receptorGLP-1 receptorPancreatic beta cellsCentral nervous system

Studies

SURPASS trials: Tirzepatide for type 2 diabetes— Journal/year not available
SURMOUNT trials: Tirzepatide for obesity— Journal/year not available

Benefits

Superior weight loss compared to semaglutide (up to 22.5% body weight)Excellent glycemic control in type 2 diabetesReduced cardiovascular riskImproved blood pressureBetter lipid profile